Debbie Doroshow @ddoroshow.bsky.social · 24/07/2026@eastsplaining.bsky.social @alexisback-11.bsky.social @basketcase3567.bsky.social @admiraljacksparrow.bsky.social @beruzebubu.bsky.social @guillegeek.bsky.social @igen-library666.bsky.social @witchypoorose.bsky.social @ya-pirat.bsky.social @ladyperiferia.bsky.social @rm4zqpfe.bsky.social 100
Debbie Doroshow @ddoroshow.bsky.social · 22/07/2026@pqchc.bsky.social @anfdeutsch.bsky.social @theshumater.bsky.social @ameurfriend.bsky.social @ifuseeksteven.bsky.social @takanashi-bug.bsky.social @cyrillatham71.bsky.social @virberrocalart.bsky.social @7271gni.bsky.social @laylavictoria.bsky.social @onelifestand87.bsky.social 010
Debbie Doroshow @ddoroshow.bsky.social · 22/07/2026@leftistlogician.bsky.social @alchemyyetti.bsky.social @tomlizard-sdw.bsky.social @kelseyforevermore.bsky.social @lzenglish.bsky.social @baneyamountain.bsky.social @4totot4.bsky.social @okazu.yuricon.com @tokusatsu.bsky.social @novinkycz.zpravobot.news.ap.brid.gy @toastyseahorse.bsky.social 000
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025And our supporting institutions: @stanford-cancer.bsky.social, @yalecancer.bsky.social, @penncancer.bsky.social, @georgetownlombardi.bsky.social, and the Tisch Cancer Institute at Mount Sinai. 020
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025TY to an incredible team for their work on this labor of love: Fauzia Riaz, John Vaughn, Huili Zhu, Jimbo Dickerson, Hoda Sayegh, Samantha Brongiel, Elena Baldwin, Melanie Kier, Jacob Zaemes, Caleb Hearn, Sam Abdelghany, Roger Cohen, Ravi Parikh, Josh Reuss, and Liz Prsic.ascopubs.orgASCO Publications 100
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025While we often hope that our patient might be the exception, our data suggests that clinical benefit from IP ICIs is very low. This may be due to the limited OS of hospitalized pts with cancer compared to the time it takes for ICIs to work. 100
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025But what about responders? 12% had a response on imaging according to treating MD. We found no clinical or demographic factors associated with OS - including pall care consult prior to rx. 6% of pts had G3 or higher irAEs including 2 deaths. 100
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025We looked at 215 patients treated with IP ICIs from 2012-2021. Three-quarters had advanced solid cancers and the same proportion were ICI naive. Median OS from the first dose of IP ICI was 1.55 mo, and among pts with adv solid tumors, 1.28 mo. 25% died in the hospital. 100
Debbie Doroshow @ddoroshow.bsky.social · 14/02/2025Many institutions disallow or limit ICIs for hospitalized pts w/cancer because they have to eat the cost. But what about clinical benefits? Our group examined clinical outcomes of pts treated with inpatient ICIs at 5 large academic institutions. ascopubs.org/doi/10.1200/... 131
